Regeneron - Evinacumab - Familial Hypercholesterolemia

Sponsored by Regeneron Pharmaceuticals , a clicnical trial is about to start to apply Evinacumab to treat Homozygous Familial Hypercholesterolemia (HoFH). Evinacumab is an FDA approved drug, the purpose of this trial is for the long-term safety and tolerability, and to evaluate the effect of evinacumab on lipid parameters in patients with HoFH.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Anticipated Study Start Date : February 8, 2018
Estimated Primary Completion Date : October 6, 2022
Estimated Study Completion Date : October 6, 2022

For enrollment, please visit

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.